Shots:

• Idorsia transfers its development & commercialization agreement with ReveraGen to Santhera- whereby Santhera shall replace Idorsia as a party to the agreement.  Santhera to get an exclusive license- including sublicensing rights- for vamorolone in all indications globally- including Japan and South Korea and a share in expected PR voucher
• In exchange for the revised license rights- Idorsia will receive 366-667 Santhera’s shares and an exchangeable note of $10.9M and is eligible to receive development & commercial milestones on sales of therapy. ReveraGen will receive $7M- in monthly installments of up to $500-000- to fund the ongoing clinical development of vamorolone
• Santhera exercises the option to get global rights to vamorolone in DMD and all other indications. ReveraGen is evaluating Vamorolone in P-IIb VISION-DMD study and expects the completion of enrollment shortly

- Click Here ­ Ref: PRNewswire | Image: Santhera